Related Experiment Video
Updated: Jul 10, 2026

08:29
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
Carbamate-linked cationic lipids for gene delivery
Dongliang Liu1, Weihong Qiao, Zongshi Li
1Key Laboratory of Science & Technology of Eco-Textile, Ministry of Education, Donghua University, North Renmin Road 2999th, Shanghai 201620, PR China. dut_liud@yahoo.com.cn
Bioorganic & Medicinal Chemistry
|October 24, 2007
Summary
New cationic lipids were synthesized for effective liposome-mediated gene delivery. Some novel liposomes demonstrated transfection efficiency comparable or superior to commercial agents in mammalian cells.
Area of Science:
- Biochemistry
- Materials Science
- Molecular Biology
Background:
- Liposome-mediated gene delivery is a promising non-viral method for genetic material transfer.
- Development of efficient and safe cationic lipids is crucial for optimizing gene delivery systems.
Purpose of the Study:
- To synthesize and evaluate a series of novel cationic lipids for liposome formulation.
- To assess the gene transfection efficiency of liposomes derived from these lipids in various mammalian cell lines.
Main Methods:
- Synthesis of cationic lipids (1a-p) with variations in hydrocarbon chain length, quaternary ammonium head groups, and carbamate linkages.
- Formation of liposomes using the synthesized cationic lipids.
- Transfection of plasmid DNA (pGL3-control, pGFP-N2) into five mammalian cell lines.
- Comparison of transfection efficiency with commercial agents (Lipofectamine2000, Sofast).
Main Results:
- Successful synthesis of a series of cationic lipids with diverse structural features.
- Formation of liposomes capable of encapsulating and delivering plasmid DNA.
- Demonstrated gene transfection efficiency in mammalian cells, with some candidates outperforming or matching commercial standards.
Conclusions:
- The synthesized cationic lipids are effective components for liposome-mediated gene delivery.
- Novel liposome formulations show potential as viable alternatives to existing commercial transfection agents.

